However, the importance of cfDNA in clinical cancer research was recognized in 1994, when point mutations of the N-RAS gene were identified in cfDNA of patients with acute myelogenous leukemia and myelodysplastic syndrome [7]. Here, NRAS is linked to myelodysplastic syndrome.